Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Objective: Decreased amyloid beta (Aβ) 42 together with increased tau and phospho‐tau in cerebrospinal fluid (CSF) is indicative of Alzheimer’s disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages. Methods: We utilized an antibody‐based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification. Results: Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP‐regulated phosphoprotein 21 (ARPP21), growth‐associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations. Interpretation: In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138 · cited 4×
“p-tau (pg/ml) [median (range)] 66 (18-213) 79 (23-213) 60 (24-158) 43 (18-157)”
InfluentialNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 3×
“p-tau (pg/ml) [median (range)] 66 (18-213) 79 (23-213) 60 (24-158) 43 (18-157)”
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 2×
“[median (range) N] 24 (7-30) 122 19 (7-30) 58 27 (21-30) 41 29 (23-30) 23”
Self-citationSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164 · cited 3×
“[median (range)] 79 (16-331) 86 (44-331) 86 (16-156) 46 (31-79)”
Self-citationAn atlas of the protein-coding genes in the human, pig, and mouse brain
Sjöstedt, E., Zhong, W., Fagerberg, L., Karlsson, M., Mitsios, N., Adori, C., Oksvold, P., Edfors, F., Limiszewska, A., Hikmet, F., et al. (2020) · Science · doi:10.1126/science.aay5947 · Cited by 1,151 · cited 3×
“p-tau (pg/ml) [median (range)] 66 (18-213) 79 (23-213) 60 (24-158) 43 (18-157)”
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Self-citation
Cited by
Aquaporin-4 and Cognitive Disorders
Wang, Y., Huang, C., Guo, Q., & Chu, H. (2022) · Aging and disease · doi:10.14336/ad.2021.0731 · Cited by 55
Asynchronous excitatory neuron development in an isogenic cortical spheroid model of Down syndrome
Li, Z., Klein, J. A., Rampam, S., Kurzion, R., Campbell, N. B., Patel, Y., Haydar, T. F., & Zeldich, E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.932384 · Cited by 24
Lizama, B. N., North, H. A., Pandey, K., Williams, C., Duong, D., Cho, E., Di Caro, V., Ping, L., Blennow, K., Zetterberg, H., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106575 · Cited by 19
Self-citationPagano, J., Perez Arevalo, A., Nosanova, A., Bauer, H. F., Loth, E., Andres, S., Becker, F., Otto, M., Stefanoni, A., Verpelli, C., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03932-8 · Cited by 2
Metadata
- Authors
- Bergström, S., Remnestål, J., Yousef, J., Olofsson, J., Markaki, I., Carvalho, S., Corvol, J., Kultima, K., Kilander, L., Löwenmark, M., Ingelsson, M., Blennow, K., Zetterberg, H., Nellgård, B., Brosseron, F., Heneka, M. T., Bosch, B., Sanchez‐Valle, R., Månberg, A., Svenningsson, P., & Nilsson, P.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2021-06-15
- Volume
- 8
- Issue
- 7
- Pages
- 1456-1470
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W3169262671
- Cited by
- 52
- References
- 24
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease. https://app.cochat.ai/papers/10.1002/acn3.51402
- The paper
- Bergström, S., Remnestål, J., Yousef, J., Olofsson, J., Markaki, I., Carvalho, S., Corvol, J., Kultima, K., Kilander, L., Löwenmark, M., Ingelsson, M., Blennow, K., Zetterberg, H., Nellgård, B., Brosseron, F., Heneka, M. T., Bosch, B., Sanchez‐Valle, R., Månberg, A., . . . Nilsson, P. (2021). Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.